Corcept Therapeutics CORT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's cash & equivalents?
- Corcept Therapeutics (CORT) reported cash & equivalents of $109.99M in Q1 2026.
- How has Corcept Therapeutics's cash & equivalents changed year-over-year?
- Corcept Therapeutics's cash & equivalents increased by 21.1% year-over-year, from $90.82M to $109.99M.
- What is the long-term trend for Corcept Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Corcept Therapeutics's cash & equivalents has grown at a 9.8% compound annual growth rate (CAGR), from $76.19M to $121.75M.
- What does cash & equivalents mean?
- The total value of cash and highly liquid investments that can be converted to cash within 90 days.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and capacity for investment, while a decrease may indicate high cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances to fund multi-year R&D pipelines.